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Gene expression in human brain implicates
sexually dimorphic pathways in autism spectrum
disorders
Donna M. Werling1, Neelroop N. Parikshak1 & Daniel H. Geschwind1,2,3,4
Autism spectrum disorder (ASD) is more prevalent in males, and the mechanisms behind this
sex-differential risk are not fully understood. Two competing, but not mutually exclusive,
hypotheses are that ASD risk genes are sex-differentially regulated, or alternatively, that they
interact with characteristic sexually dimorphic pathways. Here we characterized sexually
dimorphic gene expression in multiple data sets from neurotypical adult and prenatal human
neocortical tissue, and evaluated ASD risk genes for evidence of sex-biased expression. We
find no evidence for systematic sex-differential expression of ASD risk genes. Instead, we
observe that genes expressed at higher levels in males are significantly enriched for genes
upregulated in post-mortem autistic brain, including astrocyte and microglia markers. This
suggests that it is not sex-differential regulation of ASD risk genes, but rather naturally
occurring sexually dimorphic processes, potentially including neuron–glial interactions, that
modulate the impact of risk variants and contribute to the sex-skewed prevalence of ASD.
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A
utism spectrum disorder (ASD) is a developmental
condition characterized by deficits in social communica-
tion and restricted, repetitive behaviours or interests1 that
is estimated to affect 1 in 68 children in the United States2.
Genetic variation contributes strongly to ASD risk, as evidenced
by high familial recurrence3–5, overlap with monogenic
syndromes such as Fragile X (FMR1) or Smith–Lemli–Opitz
syndrome (DHCR7)6, and higher rates of gene-disrupting genetic
variants in ASD cases compared with their siblings or controls7–9.
The set of genes that can be definitively implicated as ASD risk
genes has been growing rapidly, and predictive models from
studies of single nucleotide variants in sporadic cases estimate
that there are likely to be hundreds of genes involved in ASD
risk8,10. Given the scope of this genetic heterogeneity,
understanding the biological aetiologies of ASD and designing
broadly applicable treatments has proven challenging.
One robust risk factor for ASD is sex: for every female with
ASD in the United States, there are 4.5 affected males2, and a
male bias in prevalence is consistent across countries and across
diagnostic criteria11. A multiple threshold liability model has
been applied to conceptualize this difference in vulnerability,
which posits that a higher minimum liability is required for
females to manifest the ASD phenotype as compared with
males12–14; this is also referred to as the female protective model.
There is now evidence from population-wide data, family-level
data14 and at the genetic level7,9,15 to support the hypothesis from
this model that autistic females with ASD carry greater genetic
liability. However, we note that a female protective model is not
incompatible with the existence of male-specific risk factors, and
the molecular mechanisms responsible for either protecting
females or potentiating males’ vulnerability remain unknown.
Several theories have been proposed regarding sex-differential
risk and protective mechanisms, though the evidence supporting
each is varied12. For example, ASD has been conceptualized as an
X-linked disorder16,17, and although several X-chromosome
genes have been implicated, numerous autosomal genes
contribute to risk as well7,8; X-chromosome genes alone do not
explain the overall male bias9,18,19. Imprinted, paternally
expressed X-chromosome genes have also been proposed to
exert protective effects on females20, though such genes have yet
to be identified. Beyond genetics, the extreme male brain theory
of autism posits that elevated prenatal testosterone exposure
increases risk21. While recent evidence has linked increased fetal
testosterone levels to later ASD diagnoses in a population
sample22, the molecular and cellular mechanisms that act to
link an early hormone exposure to a later ASD phenotype are
unknown. It is also plausible that multiple mechanisms, acting
independently or interacting with one another, collectively
account for the sex bias in ASD risk.
We reasoned that since sex-differential gene expression
patterns contribute to the development and function of a sexually
dimorphic brain, evaluating genome-wide sex-differential gene
expression in neural tissue could elucidate points of overlap with
ASD risk genes and related pathways. Here we test two basic
hypotheses about the relationship between sexually dimorphic
expression and ASD risk genes: (1) ASD risk genes are expressed
at different levels in males and females. With differing baseline
expression levels, the magnitude of the impact of a disruptive
mutation in a risk gene is likely to differ by sex. Accordingly, we
expect to observe enrichment of sex-differentially expressed (sex-
DE) genes among known ASD risk genes. (2) ASD risk genes are
expressed at the same level in males and females, but genes in
interacting molecular pathways and/or cellular processes are
differentially expressed by sex. In this case, the downstream
impact of sex-neutrally expressed ASD risk genes is likely
modulated by their interactions with sexually dimorphic
processes. If this were the case, we would expect to observe
enrichment of sex-DE genes among gene sets representing
processes associated with ASD pathophysiology, but not among
ASD risk genes themselves.
To evaluate these hypotheses, we identify sexually dimorphic
gene expression patterns in adult and prenatal human cerebral
cortex tissue and test ASD-associated gene sets for enrichment of
sex-differential expression. We observe significantly male-biased
expression patterns for microglial-function-enriched, ASD-upre-
gulated, co-expression modules from post-mortem ASD
brain23,24 and microglia and astrocyte marker genes25–27, but
no enrichment of sex-differential expression for ASD risk genes.
These patterns are most consistent with our second hypothesis,
and suggest that sex differences in biological processes captured
by specific ASD-dysregulated co-expression modules, or sexual
dimorphisms in cortical microglia and/or astrocytes, may play
critical roles in setting males’ greater risk for ASD.
Results
To identify sex-differential gene expression patterns in the human
brain, we analysed RNA-sequencing (RNA-seq) gene expression
data from human cerebral cortex tissue from the BrainSpan
project28 and from an independent, in-house data set, as well as
published array data from prenatal samples29. We focused
on cerebral cortex, since ASD risk genes are highly expressed
in this region in neurotypical brain30,31, and examination of
post-mortem autistic brain has demonstrated consistent
gene expression changes in the cerebral cortex as well23,24.
To characterize stable sex differences in gene expression, we
evaluated samples from adult subjects, and to assess sex-
differential expression during early development, when many
ASD risk genes are highly expressed, we evaluated samples from
prenatal subjects. We then tested multiple ASD risk gene sets,
ASD-associated gene sets and cell type markers for enrichment of
sex-differential expression8,23–27,32–34, to determine whether
sexually dimorphic utilization of ASD risk genes, or genes in
interacting processes, may contribute to the sex bias in ASD
prevalence.
Sex-differential expression in adult human cortex. We first
analysed RNA-seq data from 58 post-mortem cortex samples
from the BrainSpan project28 for sex-differential gene expression
using a linear mixed model. This set of samples was collected
from 10 teenage and adult subjects matched for sex, age and brain
region (13–40 years; 5 females), and filtered for outliers
(Supplementary Table 1).
Sex-differential expression patterns in adult cortex show
expected, robust differential expression of Y-chromosome genes
and XIST, an X-chromosome transcript that initiates X-chromo-
some inactivation and is only expressed in females (Fig. 1a).
We note that all Y-chromosomal transcripts that fail to show
male-biased expression are pseudogenes with high sequence
similarity to their corresponding genes on other chromosomes.
Previous studies of sex-differential expression in human brain
have preferentially reported sex-DE genes with pronounced
fold differences (FDs), such as those on the X and Y
chromosomes29,35,36. Beyond these differences driven by sex
chromosome copy number, sex-differential expression of auto-
somal and non-XIST X-chromosome transcripts are generally
subtle in magnitude37, and may reflect sex-specific tuning of
molecular pathways. Using a minimum FD magnitude of 1.2, a
standard threshold, we identify 186 genes at Po0.005, 311 genes
at Po0.01 and 866 genes at Po0.05 (Fig. 1b and Supplementary
Data 1); just 58 genes are sex-DE at a Benjamini–Hochberg
adjusted P value of 0.05, 21 of which are on the sex chromosomes.
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Figure 1 | Microglia and astrocyte markers and genes upregulated in ASD brain tend toward higher expression in adult male brain. (a) Volcano plot for
the differential expression results from all 16,392 transcripts expressed in the adult BrainSpan sample (n male¼ 29 samples from 5 subjects, n female¼ 29
samples from 5 subjects). (b) Subset of the volcano plot in a for all 15,724 autosomal transcripts. (c) Enrichment for ASD risk genes and ASD-associated
gene expression patterns, and (e) neural cell type markers, within male-DE (higher expression in males, FDX1.2, Pp0.05; 439 genes) and female-DE
(higher expression in females, FDX1.2, Pp0.05; 427 genes) gene sets by Fisher’s exact test; circle size and colour indicate the odds ratio of all significant
overlaps (Bonferroni-adjusted P value o0.05); overlaid text displays the adjusted P value for each enrichment. (d) Shifts in the distribution of sex-
differential expression direction for genes in each ASD risk or ASD expression sets, and (f) neural cell type markers. Blue and pink bars display the
proportions of each gene set that have higher expression in males (FD41) or females (FDo1); whiskers note 95% confidence intervals; horizontal black
lines note the proportion of male- and female-higher genes in the corresponding background gene set. Overlaid text displays significant Bonferroni-adjusted
P values from the binomial test. chr, chromosome; disr., disrupting; expr., expression; F, female; M, male.
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The 37 autosomal sex-DE genes, then, are not sexually dimorphic
due to copy number differences between males and females.
Instead, they may be the regulatory targets of sex steroid hormone
receptors or transcription factors from the X or Y chromosomes,
or they may be preferentially expressed in a certain cell type that
is differentially represented in male and female cortex.
Over-representation analysis for gene sets of interest. To
determine whether genes associated with ASD risk show sex-dif-
ferential expression in the human adult cortex, we examined sets of
known risk genes from several sources: (a) candidate genes from a
manually curated database32; (b) genes with rare, de novo, protein-
disrupting or missense single nucleotide variants in sporadic ASD
cases from the Simons Simplex Collection8; and (c) FMRP (Fragile
X mental retardation protein) binding targets33 (Supplementary
Data 2). Together, these gene sets capture a broad scope of ASD
risk genes, including heavily studied candidates, genes with
evidence of de novo risk variants, and genes from a strongly
ASD-associated regulatory network33. For each gene set, we first
applied a Fisher’s exact test to assess its overlap with sex-DE genes
defined by specific thresholds (FDZ1.2 and Pr0.05, Fig. 1c,
Supplementary Data 3; FDZ1.2 and Pr0.01 or Pr0.005,
Supplementary Data 3). To corroborate these results and assess
sexually dimorphic shifts in gene expression across the
transcriptome without applying arbitrary thresholds, we also used
a binomial test to assess each gene set’s distribution into two
possible outcomes: higher expression in males (FD41, any P
value), or higher expression in females (FDo1, any P value). We
found no evidence from either test for significant sex-differential
expression of any of these diverse sets of ASD risk genes in the
adult cerebral cortex, providing no evidence supporting hypothesis
1 (Fig. 1d and Supplementary Data 3).
Next, we tested gene sets with evidence of ASD-associated
expression patterns in adult human cortex23,24 (Supplementary
Data 2), neural cell type marker gene sets25–27 (Supplementary
Data 4) and genes marking cell types of the adaptive immune
system34 (Supplementary Data 5) for sex-differential expression.
We include immune cell markers in this analysis, since recent
work has suggested complementary roles for T cells and microglia
in mediating behaviour, specifically pain responses, in female
versus male animals38. The ASD-associated gene sets include
genes differentially expressed in post-mortem cortex from
subjects diagnosed with ASD24, and two ASD-associated co-
expression modules from this same study (asdM12V, down-
regulated in ASD and enriched for genes with neuronal and
synaptic functions; and asdM16V, upregulated in ASD and
enriched for genes involved in immune and inflammatory
responses)24. We also tested three ASD-associated co-
expression modules from a subsequent RNA-seq study by
Gupta et al.23, which used a larger, but overlapping set of
individuals (asdM1G, downregulated in ASD, and asdM6G,
upregulated in ASD, both modules are enriched for neuronal
markers and synaptic genes and overlap with the asdM12V
module24; asdM5G, which is upregulated in ASD, enriched for
M2-state microglial genes, and overlaps with the asdM16V
module24). These DE genes and co-expression modules
comprise large gene sets that were coherently altered in samples
of ASD cases harbouring different genetic aetiologies. Therefore,
these sets are likely to represent the downstream consequences of
deleterious variants in risk genes, an upstream or ongoing
background of molecular risk for ASD, or a secondary response to
alterations in brain function that accompany ASD, any of which
might be sexually dimorphic.
In contrast to the ASD risk genes, we observe significant
enrichment and depletion for neural cell type markers and gene
sets dysregulated in post-mortem brain from autistic subjects24.
Among genes expressed at significantly higher levels (FDZ1.2,
Po0.05) in males than in females (male-DE), we find a sevenfold
enrichment of ASD-upregulated genes (7.0-fold, Fisher-adjusted
P (PFisher_adj)¼ 1.5e-04; Fig. 1c and Supplementary Data 3).
Among genes upregulated in ASD post-mortem cortex (ASD-
up)24, 67% show higher expression in males than in females
(male-higher, 21% shift from background expectation, binomial
test-adjusted P (PBinom_adj)¼ 6.9e-03, Fig. 1d). Genes belonging
to the ASD-upregulated module asdM16V also show enrichment
for significantly male-DE genes (5.2-fold, PFisher_adj¼ 1.8e-10,
Fig. 1c) and a significant shift towards male-biased expression
overall (73% male-higher, 28% shift, PBinom_adj¼ 4.9e-21, Fig. 1d).
The related co-expression module asdM5G from Gupta et al.23
also shows this male-biased shift in expression (57% male-higher,
11% shift, PBinom_adj¼ 9.2e-08, Fig. 1d). It is critical to note that
this apparent concordance between sex and ASD status is not the
result of a male skew or lack of sex balance in the cases and
controls used by either post-mortem ASD study23,24, as all
samples consisted predominantly of males (Voineagu et al.24:
4/16 female ASD cases and 1/16 female controls; Gupta et al.23:
8/32 female ASD cases and 9/41 female controls). Both of these
published studies use multiple approaches to show that sex
confounds do not drive the observed ASD-associated gene
expression changes in brain23,24.
The ASD-upregulated gene list asdM16V, and asdM5G are
associated with astrocyte and microglial function; asdM16V
overlaps significantly with human microglial and astrocyte co-
expression modules identified in neurotypical cerebral cortex24,39
and asdM5G is enriched for gene expression signatures from M2
microglia23. Consistent with this, we also observe significant
enrichments among male-DE genes for two independently
generated sets of microglia markers (Albright et al.25: 2.1-fold,
PFisher_adj¼ 0.029; Zeisel et al.27: 6.4-fold, PFisher_adj¼ 1.8e-12,
Fig. 1e, Supplementary Data 3) and for two independently
generated sets of astrocyte markers (Cahoy et al.26: 2.4-fold,
PFisher_adj¼ 1.4e-08; Zeisel et al.27: 4.2-fold, PFisher_adj¼ 1.0e-04,
Fig. 1e); this is corroborated by significant shifts towards male-
biased expression for both astrocyte gene sets and the microglial
markers generated by single-cell RNA-seq27 (Cahoy et al.26,
astrocytes: 60% male-higher, 15% shift, PBinom_adj¼ 8.5e-37;
Zeisel et al.27, astrocytes: 69% male-higher, 23% shift,
PBinom_adj¼ 4.2e-09; microglia: 64% male-higher, 19% shift,
PBinom_adj¼ 1.7e-07, Fig. 1f).
In contrast, the forebrain neuronal marker gene set26 is
significantly enriched for genes expressed at significantly higher
levels in females than in males (FDZ1.2, Po0.05; female-DE;
1.8-fold, PFisher_adj¼ 0.019, Fig. 1e) and shifted towards female-
biased expression overall (64% with higher expression in females
(female-higher), 9% shift, PBinom_adj¼ 3.3e-11, Fig. 1f). Similarly,
genes in the ASD-downregulated, neuronal and synaptic module
asdM12V show enrichment for female-DE genes (2.7-fold,
PFisher_adj¼ 5.8e-03, Fig. 1c), while the ASD-downregulated
module asdM1G shows depletion of male-DE genes (0.37-fold,
PFisher_adj¼ 8.1e-04, Fig. 1c); both show a significant shift towards
female-biased expression overall (asdM12V: 70% female-higher,
16% shift, PBinom_adj¼ 1.0e-07; asdM1G: 64% female-higher, 10%
shift, PBinom_adj¼ 8.2e-14, Fig. 1d). No T- or B-cell modules
showed any significant enrichment with sex-DE genes or any
significant shift towards male- or female-biased expression
(Supplementary Fig. 1a).
Comparison of sex- and ASD-differential expression patterns.
We were particularly interested in the sex-DE enrichment in
the ASD-associated co-expression modules from post-mortem
brain, asdM16V and asdM12V (ref. 24). Previous studies have
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demonstrated that co-expression modules frequently correspond to
neural cell types and coherent biological functions39,40; thus, sex-
DE enrichments in these modules may most directly implicate
pathways involved in sex-biased ASD risk. Strikingly, we observe
that all 36 sex-DE genes that are also members of asdM16V are
expressed at higher levels in ASD than in control cortex24, 29 of
which are also expressed at higher levels in neurotypical male than
in female cortex (Fig. 2a). We also observe that all of the 22 sex-DE
genes in asdM12V are expressed at lower levels in ASD than in
control cortex, and 20 of these are also expressed at higher levels in
females compared with males (Fig. 2b). In short, we find
concordant directionality of differential expression by sex and
ASD status, with asdM16V sex-DE genes expressed at higher levels
in ASD and typical males and asdM12V sex-DE genes expressed at
higher levels in controls and typical females.
To assess the extent of these parallel expression patterns across
the transcriptome, we compared the FDs from sex-DE genes with
FDs observed in the differential expression analysis of ASD
cortex24. For the 374 sex-DE genes (FDZ1.2, Pr0.05) that were
also tested in the ASD-DE analysis, we observe a highly signifi-
cant positive correlation between the sex-differential and ASD-
differential FDs (r¼ 0.30, P¼ 5.7e-09, Fig. 2c), as well as for the
subset of genes differentially expressed at FDZ1.2 and Pr0.05 in
both comparisons (r¼ 0.29, P¼ 5.7e-04, N¼ 90 genes). We note
that among the 47 genes expressed at significantly higher levels in
both males and in ASD, 22 are asdM16V members24 and 19 are
astrocyte markers26 (16 belong to both sets). Among the 25 genes
expressed at significantly higher levels in both females and in
unaffected controls, 11 are asdM12V members41 and 12 are
neuron markers14 (5 belong to both sets). These results suggest
that the parallels in sex-differential and ASD-differential express-
ion direction extend beyond asdM16V and asdM12V, and that this
pattern may be more broadly indicative of sexually dimorphic
transcriptomes originating from specific neural cell types.
Independent replication of adult sex-differential expression. To
validate these observations, we next analysed RNA-seq data from
an independent sample of adult cortex tissue (16–56 years,
Supplementary Table 1) for sex-differential expression patterns.
Using this smaller data set, we identify 65 genes at Po0.005, 98
genes at Po0.01 and 519 genes at Po0.05 (Supplementary
Fig. 2a,b and Supplementary Data 1). Overall, sex-DE genes from
the BrainSpan data were expressed at comparable levels and with
positively correlated fold differences in this independent sample
(expression levels: r¼ 0.78, P¼ 2.9e-150; log2(FD)s, r¼ 0.57,
P¼ 3.6e-65; Fig. 3a). We observed no over-representations of
ASD risk genes among significantly sex-DE genes (FDZ1.2,
Po0.05) from these data (Supplementary Fig. 2d and
Supplementary Data 6); however, FMRP targets were more likely
to show higher expression in females than in males (62% female-
higher, 13% shift, PBinom_adj¼ 2.9e-10, Supplementary Fig. 2d).
Oligodendrocyte markers and endothelial cell markers also
showed shifts towards female-biased expression (Cahoy et al.26
oligodendrocytes: 56% female-higher, 9% shift, PBinom_adj¼ 1.5e-
11; Zeisel et al.27 oligodendrocytes: 59% female-higher, 15% shift,
PBinom_adj¼ 5.8e-07; endothelial cells27: 55% female-higher, 11%
shift, PBinom_adj¼ 5.7e-03, Supplementary Fig. 2f). We also found
depletion of male-DE genes in asdM1G (0.26-fold,
PFisher_adj¼ 0.027, Supplementary Fig. 2c), but enrichments for
asdM16V genes (4.7-fold, PFisher_adj¼ 2.8e-03; 64% male-higher,
11% shift, PBinom_adj¼ 5.2e-03, Supplementary Fig. 2c,d), asdM6G
genes (58% male-higher, 7% shift, PBinom_adj¼ 0.014, Supple-
mentary Fig. 2d), astrocyte marker genes (Cahoy et al.26: 61%
male-higher, 10% shift, PBinom_adj¼ 1.7e-16; Zeisel et al.27: 69%
male-higher, 18% shift, PBinom_adj¼ 6.6e-06, Supplementary
Fig. 2f) and ependymal cell markers (60% male-higher, 9%
shift, PBinom_adj¼ 0.027, Supplementary Fig. 2f). Again, we find
no sex-differential expression signal in T- and B-cell modules
(Supplementary Fig. 1b and Supplementary Data 6). Of the 164
genes expressed more highly in males with a FDZ1.2 in both
adult data sets, 24 are asdM16V members (8.8-fold enrichment,
P¼ 5.5e-14) and 70 are astrocyte markers (10.3-fold enrichment,
P¼ 3.3e-35; 14 of these genes are belong to both sets), further
supporting the characterization of astrocytic genes and ASD-
upregulated, microglial-function-enriched asdM16V genes, as
displaying male-biased expression in the adult human cortex
(Fig. 3b).
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Sex-differential expression in prenatal human cortex. One
possible explanation for the lack of enrichment of ASD risk genes
among sex-DE genes from adult brain is that ASD risk genes may
be acting primarily during fetal brain development30,31. To
address this, we next analysed array expression data from 86
neocortex samples from 8 subjects (4 females) between 16–22
post-conception weeks29 (Supplementary Table 1). This prenatal
epoch follows the mid-gestation peak in testosterone secretion
from males’ differentiated testes42,43 and thus captures a stage
during which steroid hormones are likely to be exerting
organizational effects.
We find 306 sex-DE genes at Po0.005, 440 sex-DE genes at
Po0.01 and 1,037 sex-DE genes at Po0.05, with 96 genes sex-DE
at an adjusted Po0.05 (Fig. 4a,b and Supplementary Data 1).
Results from over-representation analysis for the gene sets of
interest within these prenatally sex-DE genes mirror those in the
adult data: there are no significant enrichments for ASD risk gene
sets, and FMRP interactors are significantly depleted within male-
DE genes (0.33-fold, PFisher_adj¼ 8.0e-04, Fig. 4c, Supplementary
Data 7).
As in adult brain, genes expressed more highly in prenatal male
cortex show robust enrichments for post-mortem cortex ASD-
upregulated genes (4.6-fold, PFisher_adj¼ 3.3e-03, Fig. 4c),
asdM16V genes (4.0-fold, PFisher_adj¼ 2.6e-09; 67% male-higher,
16% shift, PBinom_adj¼ 6.2e-05, Fig. 4c), asdM5G genes (2.9-fold,
PFisher_adj¼ 5.1e-09; 61% male-higher, 13% shift, PBinom_adj¼ 4.2
e-07, Fig. 4c,d), microglia markers (Albright et al.25: 2.1-fold,
PFisher_adj¼ 2.8e-03; 60% male-higher, 11.4% shift, PBinom_adj¼
1.2e-04; Zeisel et al.27: 2.9-fold, PFisher_adj¼ 0.027, Fig. 4e,f),
endothelial markers (3.7-fold, PFisher_adj¼ 3.2e-06, Fig. 4e) and a
significant depletion of forebrain neuron marker genes (0.41-fold,
PFisher_adj¼ 2.3e-05; 58% female-higher, 7% shift, PBinom_adj¼
1.3e-04, Fig. 4e,f). As in adult, T- and B-cell modules show no
enrichments or depletions of sex-DE genes, nor any sex-skewed
expression shifts (Supplementary Fig. 1c and Supplementary Data 7).
Taken together, these findings fail to support the hypothesis
that ASD risk genes are differentially expressed by sex in the
human cerebral cortex. Rather, we observe that sex-DE genes are
enriched among specific classes of changes observed in post-
mortem cortex from ASD patients, which is indicative of shared
biology between ASD and typical sexual dimorphisms. These
patterns of sex-DE enrichment follow what is observed in ASD
cortex, with higher expression of microglial and astrocyte genes
(exemplified by asdM16V and asdM5G) in the more susceptible
male population, and higher expression of a cohort of synaptic
genes (exemplified by asdM12V), in the more protected, female
population.
Discussion
Autism risk is sexually dimorphic, and genetic studies are most
consistent with a female protective effect. To begin to explore
potential mechanisms mediating sex-differential genetic risk, we
tested the hypothesis that ASD risk genes would show sexually
dimorphic expression in the cerebral cortex, a region that plays a
major role in complex human cognitive phenotypes, including
social behaviour, and where many ASD genes are expressed30,31.
We observe both in adult and fetal brain that while some ASD
risk genes do show sex-differential expression, overall this is not
beyond what would be expected by chance. Furthermore, these
sex-neutral expression patterns are evident in the mid-fetal
cortex, a spatiotemporal point of convergence for ASD risk genes’
expression30,31.
Instead, we find support for a second hypothesis: that genes
whose expression patterns are altered in post-mortem autistic
brain, which highlight downstream or interacting pathways, but
not ASD risk genes themselves, are differentially expressed by sex.
The convergence of male-DE genes with these downstream
pathways, but not with risk genes or neuronal markers, is
consistent with the evidence presented by Voineagu et al.24:
asdM16V is upregulated in ASD brain and enriched for immune
system function and inflammatory response genes, but not for
common ASD susceptibility variants. The asdM16V module is
therefore interpreted as representing a secondary, likely
downstream effect of genetically causal perturbations. Whether
a secondary effect of genetic variants or a result of independent
mechanisms, it may be that expression of this gene set beyond a
certain threshold is detrimental to neural development and
function. Our findings show that typical males land closer to
this putative threshold than females do, potentially implicating
these genes expressed at higher levels in the male and ASD cortex
in mechanisms driving male-biased ASD risk. Furthermore,
to the extent that asdM16V upregulation contributes to ASD
pathophysiology, this module may serve as a useful target for
pharmacological treatments that could modulate the effects of
heterogeneous risk variants acting upstream.
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Alternatively or concordantly, it may also be the case that
ASD-protective genes are expressed at a higher level in females.
Genes in the neuronal- and synapse function-enriched asdM12V
module may represent such a protective gene set, as these
genes are downregulated in ASD post-mortem cortex24. Genes
belonging to asdM12V do show higher expression in adult female
cortex from the BrainSpan sample (Fig. 1c,d), though neither the
replication adult sample nor the prenatal sample show this same
female skew. Alternatively, the relatively sex-neutral expression of
asdM12V genes in contrast to asdM16V may simply reflect the
absence of a particular ASD pathophysiological process in
neurotypical samples.
We also observed a correlation in the relative FDs of sex-DE
genes and ASD-DE genes that extends beyond the asdM16V
module, such that genes expressed more highly in typical male
cortex also tend to be more highly expressed in ASD cortex, while
genes more highly expressed in typical female cortex also tend to
be expressed at lower levels in ASD cortex24. Again, we
emphasize this agreement in fold change direction between sex
and ASD status is not likely the result of a male-confounded
analysis by Voineagu et al.24 or Gupta et al.23, as cases and
controls were sex balanced, and any potential sex effects were also
regressed out in those studies. Interestingly, the gene expression
patterns we observe fit squarely with hypotheses derived from
both the extreme male brain theory and from the concept of
female protective factors in ASD: male-DE (ASD-upregulated)
genes could act to increase risk, while female-DE (ASD-
downregulated) genes could have protective functions.
However, we caution that FDs do not indicate the underlying
mechanism of gene regulation (that is, active upregulation in
males can return the same result as repression in females). We
cannot yet conclude that parallel expression differences between
the sexes and in ASD are derived from the same regulatory
mechanisms, but this work provides a starting point for their
study. Additional experiments that include sufficient numbers of
cases and controls of both sexes will be necessary to tease apart
how sex and ASD status interact to affect gene expression, for
example, to determine whether male-DE genes are expressed at
even higher levels in ASD cases.
Astrocyte and microglial markers are also reliably enriched
among male-DE genes in both adult and prenatal cortex. We
recognize two possible explanations for this: (1) a greater
proportion of astrocytes and microglia to neurons in male cortex
results in higher measured gene expression in males; or (2) males’
cortical astrocytes and microglia are more transcriptionally active
than females’. Aside from early, tenuous observations of greater
cortical neuron density in males44, sex differences in the cellular
composition of human cortex have not been sufficiently
characterized to determine if there is a greater number of
certain glial subtypes in male cortex. In contrast, there is clear
evidence for sexually dimorphic astrocyte morphology in animals,
particularly in hypothalamic nuclei, with male astrocytes showing
a greater number of longer and more branched processes45–47. In
addition, sex steroid hormones may play a role in astrocyte
differentiation and regulation, as oestrogen receptors are
expressed in hypothalamic and hippocampal astrocytes48,49, and
female animals exposed to testosterone neonatally show male-
typical astrocyte morphology46. Given the participation of
astrocytes in the modulation of neurotransmission50,51 and of
microglia and astrocytes in synapse formation and function52–55,
it is plausible that sexual dimorphisms in astrocyte and/or micro-
glia number or function would lead to sex-differential effects
on neuronal connectivity56. It is also interesting to consider
that numerous ASD risk genes function at the synapse7,9,57–59,
and that as a third synaptic component along with pre- and
postsynaptic neurons, sexually dimorphic astrocytes and/or
microglia are well positioned to broadly influence the effects of
upstream, heterogeneous risk variants.
We also acknowledge several limitations of our study. First, our
analyses utilize gene expression data from the human cerebral
cortex, a region that other studies have indicated is a convergent
area where many ASD risk genes likely exert their action30,31.
However, other brain regions not sampled in our data sets, such
as the hypothalamic nuclei, are known to be robustly sexually
dimorphic60. It may be that ASD risk genes are differentially
expressed by sex in these sexually dimorphic regions, or that it is
the connections between these regions and other parts of the
brain where the sex-differential risk-modulatory mechanisms act
(as opposed to purely within-cortex interaction at the level of
molecular pathways and local cell–cell connections). Assessment
of additional brain regions, including hypothalamic nuclei and
other subcortical structures, in sufficiently powered test and
replication sets will be useful for addressing this important
question, once such data are available.
The mechanism(s) of the sex-biased expression observed
here are not known, but present significant opportunities for
understanding ASD’s sex-biased pathogenesis. For example,
transcription of sex-DE genes identified here may be regulated
by sex-differential factors, such as transcription factors from
the sex chromosomes, or by sex steroid receptor binding to
hormone response elements upstream from transcription start
sites. Chromatin immunoprecipitation experiments in human
neural tissue coupled with functional assays in model systems will
be needed to thoroughly characterize binding sites for these
regulatory elements throughout the genome.
Alternatively, the sex differences we have observed may not
result from differential transcription regulation, but instead from
sex differences in the proportions of different neural cell types
within male and female tissue. The overlap between male-DE
genes and astrocyte and microglial marker genes is consistent
with this possibility, although the processes that lead to sex
differences in cell type proliferation or differentiation are unclear.
Quantitative histological studies of male and female human brain
will be critical to characterize the extent to which cell type
composition differs between the sexes, and neurodevelopmental
follow-up will be required to demonstrate how these differences
arise.
The extent to which the convergent transcriptional changes
previously observed in ASD cortex23,24 represent causal aetio-
logies versus consequences of brain dysfunction also remains to
be delineated61. In the case of ASD-associated co-expression
modules enriched for risk variants, such as asdM12V, enrichment
of genes carrying ASD risk variants provides evidence for a
causal, primary role in ASD aetiology. However, ASD-associated
co-expression modules that lack enrichment for genetic risk
variants, such as asdM16V, may be linked to ASD in one of
several ways: (1) They reflect direct downstream consequences
of variants in, or dysregulation of, primary, ‘causal’ genes (for
example, asdM12V) that actively participate in the patho-
physiological processes that shape and maintain an autistic-
functioning brain; (2) they represent risk pathways that are
independent of primary risk genes, for example, consequences of
an environmental exposure, that also actively participate in ASD’s
aetiology; or (3) they exemplify consequences of living with ASD
to the brain, which may modify the presentation of ASD or its
comorbidities, but that do not have a role in ASD’s aetiology. For
example, the gene expression signature captured by non-variant-
enriched, co-expression module asdM16V, which is upregulated
in post-mortem adult autistic cortex, may reflect the impact of
chronic social stress experienced across the lifespan. If male and
female brains respond differently to stress62, then the concor-
dance we observe between these gene expression signatures may
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be tangential to ASD’s primary pathophysiology. Though, one
would expect that such stress would be cumulative over the
lifespan, so that a stress-driven gene expression profile would
increase with experience and age. Neither of the ASD-associated
co-expression modules is significantly correlated with age23,24,
making this explanation less likely. Nevertheless, extensive
characterization of animal models of ASD genetic risk variants,
including gene expression patterns, may help to determine
whether expression signatures like these are purely consequential,
or if they are evident during early development and play a role in
ASD aetiology.
In any case, the sex-DE patterns that we observe in multiple,
independent samples demonstrate that currently identified ASD
risk genes are not innately sex-differentially expressed in the
developing or adult human cerebral cortex. Instead, it is the
molecular, cellular or circuit-level context in which ASD risk
genes operate that is likely responsible for modulating ASD
liability in a sex-differential manner. This notion fits with the
remarkable consistency of the male bias in ASD prevalence,
despite ongoing evidence of considerable genetic heterogeneity in
ASD. Study of astrocyte–neuronal and microglia–neuronal
synapse interactions, and study of the causes and functional
consequences of higher expression of astrocyte and microglial
genes in male brain and synaptic genes in female brain, are
needed to determine how sex-differential functioning of these
pathways impact sexually dimorphic risk for a variety of
neurodevelopmental disorders, including ASD.
Methods
Adult BrainSpan data set. Developmental RNA-seq data from the BrainSpan
project28 summarized to Gencode 10 (ref. 41) gene-level reads per kilobase million
mapped reads (RPKM) were used. Data were normalized for GC content, using
conditional quantile normalization63, batch-corrected for processing site using
ComBat64 and log2-transformed (log2(RPKMþ 1)). Samples from regions of the
frontal, temporal and parietal cortex from subjects aged 13–40 years, with RNA
integrity number (RIN) of at least 8.0, were retained for this analysis. Non-
expressed genes defined as having a log2-transformed RPKM expression level of
o1 in more than 50% of all male or female samples were removed. Outlier samples
were identified by evaluating inter-sample correlations and hierarchical clustering,
first within each sex, and then on the full data set (samples of both sexes considered
together); samples with inter-sample correlations 42.5 s.d.’s from the mean
were removed. The data were then quantile normalized to mitigate the effects of
systematic differences in the distribution of expression levels across samples on the
differential expression analysis results. After gene filtering and outlier removal,
72 samples (29 from males and 43 from females) and 16,843 expressed genes
remained. To balance the male and female sample sets, we then matched a subset of
the female samples to the male samples by age and brain region, and again filtered
for expressed genes. The final data set consisted of 58 samples from 10 subjects
(29 samples from 5 subjects of each sex; Supplementary Table 1) and 16,392 genes
(Supplementary Data 1).
Adult replication data set. The adult replication sample comprised seven frontal
and temporal cortex samples from five male individuals matched to seven cortical
samples from five female individuals with no history of neuropsychiatric or neuro-
logical diagnoses. Male and female samples were matched for age, post-mortem
interval (PMI) and brain region. These samples were a subset of a larger set
acquired from the Harvard Brain and Tissue Bank and the Eunice Kennedy Shriver
National Institute for Child Health and Human Development Brain and Tissue
Bank for Developmental Disorders following the tissue acquisition policies of the
respective brain banks.
Approximately 100mg of tissue from each sample was dissected on dry ice;
RNA isolations were performed using the miRNeasy kit (Qiagen), RNA quality was
quantified using the RIN65 and ribosomal RNA was depleted using the Ribo-Zero
Gold kit (Epicentre). Remaining RNA was then size selected with AMPure XP
beads (Beckman Coulter) and re-suspended, and sequencing libraries with indexed
adaptors were prepared according to the Illumina TruSeq protocol. Fifty base-pair,
paired-end reads were generated on a HiSeq 2000/2500, with 24 samples pooled
per lane.
Reads were mapped to the human reference genome (hg19) using Gencode v18
annotations with TopHat2, allowing for up to 10 multiple mappings per read41,66.
Output BAM files were filtered to ensure that every read had a valid pair, resulting
in only paired-end reads (fragments) being used for downstream analyses.
Transcript levels were quantified using Gencode v18 gene models at the union gene
model level using HT-seq Counts67. We normalized these data for GC content
biases using the cqn package in R (ref. 63), which resulted in log2(normalized
FPKM) values, and ensured that there were no sample outliers with a summed
sample correlation Z-score42 (ref. 68). Genes not expressed in the subset of
neurotypical samples selected for these analyses were identified (log2-transformed
FPKM expression level o1 in more than 50% of all male or female samples) and
removed. Outlier samples with inter-sample correlations 42.5 s.d.’s from the
mean, either within each sex or within the complete sample set, were removed. The
expression data for the remaining samples were then quantile normalized. The final
filtered data set consisted of 13 samples from 10 subjects (Supplementary Table 1),
and 19,354 genes (Supplementary Data 1).
Prenatal data set. Exon array data analysed by Kang et al.29 and downloaded
from the Gene Expression Omnibus (GSE25219) were used for the assessment
of prenatal gene expression. Only samples from subjects between 16 and 22 post-
conception weeks from the frontal, temporal and parietal cortex, and with RIN
of 8.0 or greater were used in this stage of analysis.
Probe set IDs from the downloaded data were matched to Ensembl Gene IDs
from Gencode 10 using the biomaRt function in R. Non-expressed genes were
defined as those genes with a log2-transformed median probe set intensity ofo6 in
480% of male or female samples within the selected sample set, and were
removed. Outlier samples were detected by evaluating inter-sample correlations
and hierarchical clustering within each sex and within the complete data set, and
samples with inter-sample correlation 42.5 s.d.’s from the mean were removed.
Expression data for the remaining samples were quantile normalized. After these
processing steps, 142 samples (43 from males and 99 from females) and 9,985
expressed genes remained. To balance the number of male and female samples for
analysis, we then matched a subset of the female samples to the male samples on
age and brain region, and again filtered for expressed genes. The final data set
consisted of 86 samples from 8 subjects (43 samples from 4 subjects of each sex;
Supplementary Table 1), and 9,889 genes (Supplementary Data 1).
Differential expression analysis. Differential expression analyses for all data sets
were performed using a linear mixed model and Bayesian t-tests as implemented in
LIMMA69, a robust method for analysing small samples. For all analyses, the main
contrast in the regression model was sex, and subject was included as a random
effect to account for the non-independence of samples from the same individual
brain (that is, different brain regions). Covariates were included, where available, in
the model as fixed effects: RIN, age, PMI, cortical lobe and pH for the adult
BrainSpan data; RIN, age, PMI and cortical lobe for the replication data; and RIN,
age, PMI, cortical lobe and pH for the prenatal data. Per-subject average values
were substituted for missing PMI and pH information. Genes with a FD magnitude
of 1.2 or greater and an unadjusted P value of 0.005, 0.01 or 0.05 were called as
differentially expressed by sex (sex-DE; Supplementary Data 1).
Annotation gene sets. ASD candidate genes were selected from the SFARI Gene
Autism Database32 and filtered to those genes classified as syndromic (category S)
or with evidence levels between 1–4 for a set of 153 genes. To also investigate a risk
gene set based on evidence from an unbiased, experimental screen, we used the set
of genes with rare de novo variants (RDNVs) in sporadic ASD cases from exome
sequencing of families from the Simons Simplex Collection8. All genes with
RDNVs in autistic probands were compiled and classified as protein-disrupting
(nonsense, splice site or frameshift mutations), missense or silent variants. Here we
use the gene set with protein-disrupting variants (353 genes) and the expanded
gene set with either protein-disrupting or missense variants (1,771 genes). We also
evaluated the set of transcripts that are binding targets of FMRP, a functionally
defined gene set that is enriched for ASD risk genes70. Here we tested the 725
human orthologues of FMRP target genes as characterized in mouse brain33
(Supplementary Data 2).
Seven gene sets with ASD-associated expression patterns in adult human cortex
were also tested. From a 2011 study by Voineagu et al.24, we tested genes expressed
at significantly (1) higher (FDZ1.2, q-valueo0.1, 88 genes) or (2) lower levels in
ASD than in control cortex (125 genes); (3) ASD-associated, unsigned co-
expression modules from weighted gene co-expression network analysis, asdM12V
(downregulated in ASD, 414 genes); and (4) asdM16V (upregulated in ASD, 361
genes). From a 2014 study by Gupta and colleagues23 that used a larger, but
overlapping, sample of individuals as Voineagu et al.24, but which analysed BA19, a
different cortical region, we tested several ASD-associated weighted gene co-
expression network analysis modules, including (5) asdM1G (downregulated in
ASD, 1,643 genes), (6) asdM6G (upregulated in ASD, 667 genes) and (7) asdM5G
(upregulated in ASD, 759 genes) (Supplementary Data 2).
Since gene expression patterns in the brain often reflect the transcriptional
activity of distinct neural cell types39,40, we also culled gene sets marking different
cell types from several studies in the literature. From a microarray study of sorted
cell types in mouse forebrain26, we tested markers for neurons (1,489 genes),
oligodendrocytes (1,626 genes) and astrocytes (1,968 genes). From a microarray
study of human microglial cells in culture25, we tested genes with at least a twofold
upregulation in activated, microglia-enriched, mixed glial cultures (B60%
microglia) (773 genes). From a single-cell RNA-seq study of mouse somatosensory
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cortex and hippocampus27, we tested markers for CA1 pyramidal neurons (355
genes), S1 pyramidal neurons (235 genes), interneurons (319 genes),
oligodendrocytes (397 genes), astrocytes
(216 genes), microglia (368 genes), endothelial cells (312 genes), ependymal cells
(402 genes) and mural cells (pericytes and vascular smooth muscle cells, 137 genes)
(Supplementary Data 4).
Recent evidence has also suggested complementary roles for microglia and
immune cells in mediating behaviour in male versus female animals38. To evaluate
whether adaptive immune cells contribute to the sex-differential gene expression
that we observe in the brain, we tested co-expression modules generated by the
Immunological Genome Project from mouse haematopoietic cells that are
associated with T- and B-cell lineage regulator genes34: T-cell module 18 (106
genes); gamma delta T-cell module 65 (30 genes); gamma delta, natural killer T and
T4 module 56 (58 genes); alpha beta T-cell module 57 (52 genes); B-cell module 33
(125 genes); B-cell module 61 (38 genes); and B-cell module 76 (15 genes;
Supplementary Data 5).
For the enrichment analyses, we used the following gene sets as background: for
SFARI candidate genes, genes with RDNVs in ASD cases and activated microglial
markers, we used expressed genes with a Gencode biotype annotation of ‘protein
coding’; for gene sets with ASD-associated expression patterns and for immune
cell markers, we used expressed genes also tested in the corresponding source
publication23,24,34; and for FMRP target genes33 and cell type markers from
Cahoy et al.26 and Zeisel et al.27, we used the genome-wide set of one-to-one
human–mouse orthologues as background (Supplementary Data 8).
For all background and gene sets of interest, gene identifiers were converted to
Ensembl Gene IDs in Gencode using the biomaRt package in R to allow for
unambiguous comparisons between genes from different data sources. Gene set
membership, background set membership and sex-DE categorization for all
expressed genes tested for differential expression in the three data sets are recorded
in Supplementary Data 9.
Over-representation analysis. To evaluate the enrichment of gene sets of interest
among sex-DE genes, we applied a two-sided Fisher’s exact test separately to
sex-DE gene sets expressed more highly in males (male-DE) and in females
(female-DE) at three P value thresholds (unadjusted Po0.005, 0.01 and 0.05,
Supplementary Data 3, 6 and 7) in R. P values from the Fisher’s exact tests run
within each data set were adjusted for 62 tests performed against the 31 gene sets of
interest (4 ASD risk gene sets, 7 ASD expression gene sets, 13 neural cell type
marker sets and 7 adaptive immune cell marker sets) at each of the three sig-
nificance levels for the sex-DE input genes.
To further investigate patterns of sexually dimorphic expression within each
gene set of interest without applying arbitrary thresholds to define sex-DE genes,
we also assessed the distribution of the genes in each set into two mutually
exclusive categories: higher expression in males (positive log2(fold difference), at
any P value); or higher expression in females (negative log2(fold difference), at any
P value). We then applied a two-sided binomial test against the distribution of
male-higher and female-higher genes in the corresponding background gene set
(Supplementary Data 3, 6 and 7). P values from all binomial tests within each data
set were Bonferroni-corrected for the 31 gene sets tested.
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